Pharmaceuticals

C5 Complement Inhibitors Market Expected to Reach $14.93 Billion by 2030 at a CAGR of 13.7%

March 29, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Much Is The C5 Complement Inhibitors Market Expected To Grow In Terms Of Market Value Between 2026 And 2030?

In recent years, the c5 complement inhibitors market size has seen swift expansion. This market is projected to expand from $7.84 billion in 2025 to $8.93 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 13.9%. Historically, this growth was driven by factors such as the approval of pioneering complement inhibitors, an increase in the diagnosis of rare hematological conditions, enhanced clinical understanding of complement pathways, the proliferation of specialized treatment facilities, and robust biologics development pipelines.

The c5 complement inhibitors market size is anticipated to undergo substantial growth in the upcoming years. It is forecast to achieve a valuation of $14.93 billion by 2030, propelled by a compound annual growth rate (CAGR) of 13.7%. This expansion in the projected period can be attributed to the rising prevalence of autoimmune and rare diseases, the broadening scope of personalized medicine approaches, an expanding pipeline of next-generation inhibitors, increased biologics manufacturing capacity, and supportive regulatory frameworks for orphan drugs. Noteworthy trends for the forecast period include the increasing adoption of targeted immunotherapies, their growing application in rare complement-mediated disorders, a rising preference for long-acting formulations, the proliferation of combination treatment strategies, and an intensified focus on early diagnosis and intervention.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23334&type=smp

What Key Drivers Are Influencing The Growth Of The C5 Complement Inhibitors Market?

The projected expansion of the C5 complement inhibitors market is fueled by the rising incidence of chronic diseases. These are enduring health conditions characterized by gradual progression and prolonged duration, frequently necessitating ongoing medical care and supervision to avert complications. The growing occurrence of chronic diseases primarily stems from shifts in lifestyle, including inadequate nutrition, lack of physical activity, tobacco use, and stress, all of which lead to a gradual decline in health. C5 complement inhibitors assist individuals with chronic diseases by inhibiting the excessive activation of the complement system, which in turn diminishes inflammation, safeguards against tissue harm, and enhances patient results in conditions like PNH, aHUS, and other related disorders. For example, an April 2025 report from the International Diabetes Federation, a non-profit organization based in Belgium, indicated that in 2024, over 9.5 million individuals were affected by type 1 diabetes, a figure that included 1.9 million children and adolescents under 20. Projections suggest that the worldwide diabetes population will escalate to 853 million by 2050. Consequently, the rising occurrence of chronic illnesses is a key factor propelling the expansion of the C5 complement inhibitors market.

What Major Segment Divisions Exist Within The C5 Complement Inhibitors Market?

The c5 complement inhibitors market covered in this report is segmented –

1) By Product: Long Acting C5 Inhibitors, Short Acting C5 Inhibitors

2) By Drug: Eculizumab, Ravulizumab, Other Drugs

3) By Route Of Administration: Intravenous, Subcutaneous

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies

5) By Application: Paroxysmal Noctural Hemoglobuinuria, Atyptical Hemolytic Uremic Syndrome, Generalized Myasthenia Gravis, Neuromyelitis Optics Spectrum Disorder, Other Applications

Subsegments:

1) By Long Acting C5 Inhibitors: Crovalimab, Pozelimab, Tesidolumab, Other Long-Acting C5 Inhibitors

2) By Short Acting C5 Inhibitors: Zilucoplan, Cemdisiran, Nomacopan, Other Short-Acting C5 Inhibitors

How Are Trends Shaping The Direction Of The C5 Complement Inhibitors Market?

Major companies operating in the C5 complement inhibitors market are concentrating on creating innovative therapies, including self-administered C5 inhibitors, to broaden the available treatment options for generalized myasthenia gravis. This kind of inhibitor serves as a targeted therapeutic agent that functions by blocking the complement C5 protein to mitigate inflammation and immune-mediated damage, and is designed for patient self-administration to address conditions such as paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. An example of this occurred in October 2023, when Union Chimique Belge (UCB) SA, a Belgium-based biopharmaceutical company, revealed the approval of Zilbrysq (zilucoplan) by the Food and Drug Administration (FDA), a US-based government regulatory agency, for use in treating adults with generalized myasthenia gravis (gMG). This specific approval is applicable to patients identified as anti-acetylcholine receptor (AChR) antibody-positive, which is a common manifestation of the disease. Zilbrysq itself is a self-administered, once-daily, subcutaneous C5 complement inhibitor, thereby presenting a new therapeutic choice for gMG patients. The approval consequently enhances UCB’s neurology portfolio, extending the range of treatment choices for individuals affected by autoimmune neuromuscular disorders.

Which Companies Are Leading Innovation In The C5 Complement Inhibitors Market?

Major companies operating in the c5 complement inhibitors market are AstraZeneca plc, F. Hoffmann-La Roche AG, Chugai Pharmaceutical Co. Ltd., Swedish Orphan Biovitrum AB, Alnylam Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., Omeros Corporation, Dianthus Therapeutics Inc., Akari Therapeutics Plc, Regeneron Pharmaceuticals Inc., UCB Pharma SA, Astellas Pharma Inc., InflaRx NV, Alexion Pharmaceuticals Inc., Ra Pharmaceuticals Inc., ChemoCentryx Inc., Annexon Biosciences Inc., Iveric Bio Inc., Apellis Pharmaceuticals Inc., Kira Pharmaceuticals Inc.

Read the full c5 complement inhibitors market report here:

https://www.thebusinessresearchcompany.com/report/c5-complement-inhibitors-global-market-report

Which Region Is Expected To Register The Fastest Growth In The C5 Complement Inhibitors Market?

North America was the largest region in the C5 complement inhibitors market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the c5 complement inhibitors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored C5 Complement Inhibitors Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=23334&type=smp

Browse Through More Reports Similar to the Global C5 Complement Inhibitors Market 2026, By The Business Research Company

Cc Chemokine Receptor Type 5 Market Report 2026

https://www.thebusinessresearchcompany.com/report/cc-chemokine-receptor-type-5-global-market-report

Ace Inhibitors Market Report 2026

https://www.thebusinessresearchcompany.com/report/ace-inhibitors-global-market-report

Kinase Inhibitors Market Report 2026

https://www.thebusinessresearchcompany.com/report/kinase-inhibitors-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795